OpenLB
Open Library of Bioscience
Advanced Search
Vaccine
Jun 23, 2010;28 (29): 4653-60.

The potential economic value of a Staphylococcus aureus vaccine for neonates.

Bruce Y Lee, Paul J Ufberg, Rachel R Bailey, Ann E Wiringa, Kenneth J Smith, Andrew J Nowalk, Conor Higgins, Angela R Wateska, Robert R Muder
Author Information
  1. Bruce Y Lee: Applied Modeling, Public Health Computational and Operations Research (PHICOR), Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA 15213, USA. BYL1@pitt.edu
PMID: 20472028 DOI: 10.1016/j.vaccine.2010.04.069

Abstract

The continuing morbidity and mortality associated with Staphylococcus aureus (S. aureus) infections, especially methicillin-resistant S. aureus (MRSA) infections, have motivated calls to make S. aureus vaccine development a research priority. We developed a decision analytic computer simulation model to determine the potential economic impact of a S. aureus vaccine for neonates. Our results suggest that a S. aureus vaccine for the neonatal population would be strongly cost-effective (and in many situations dominant) over a wide range of vaccine efficacies (down to 10%) for vaccine costs (or=1%).

References

  1. Future Microbiol. 2007 Feb;2(1):1-3 [PMID: 17661669]
  2. Med Care. 2008 Apr;46(4):349-56 [PMID: 18362813]
  3. J Hosp Infect. 1995 Oct;31(2):123-34 [PMID: 8551018]
  4. Pediatr Infect Dis J. 2006 Feb;25(2):167-8 [PMID: 16462297]
  5. Int J Epidemiol. 2015 Oct;44(5):1549-56 [PMID: 26108436]
  6. Infect Control Hosp Epidemiol. 2008 Nov;29(11):996-1011 [PMID: 18947320]
  7. Vaccine. 2007 Jan 15;25(5):814-24 [PMID: 17027124]
  8. J Clin Microbiol. 2006 Feb;44(2):655-6 [PMID: 16455939]
  9. J Hosp Infect. 2002 Jan;50(1):18-24 [PMID: 11825047]
  10. Int J Antimicrob Agents. 2008 Nov;32 Suppl 1:S71-8 [PMID: 18757184]
  11. Arch Dis Child. 2005 Jul;90(7):720-3 [PMID: 15970616]
  12. Am J Infect Control. 2009 Apr;37(3):195-200 [PMID: 19181423]
  13. JAMA. 1981 Apr 24;245(16):1662-4 [PMID: 6907329]
  14. Med Care. 1998 Jun;36(6):778-92 [PMID: 9630120]
  15. Am J Med. 2002 Sep;113(4):300-7 [PMID: 12361816]
  16. Pediatr Clin North Am. 2006 Aug;53(4):699-713 [PMID: 16873000]
  17. BMC Infect Dis. 2006 Jun 23;6:103 [PMID: 16796741]
  18. J Hosp Infect. 1995 May;30(1):65-72 [PMID: 7665884]
  19. Pharmacoeconomics. 1995 Aug;8(2):147-58 [PMID: 10155609]
  20. J Perinatol. 2010 Feb;30(2):135-9 [PMID: 19710681]
  21. Pediatr Infect Dis J. 1992 Feb;11(2):82-7 [PMID: 1741203]
  22. Pediatr Infect Dis J. 2009 Jul;28(7):577-81 [PMID: 19478687]
  23. J Med Microbiol. 2009 Mar;58(Pt 3):376-380 [PMID: 19208891]
  24. Pediatrics. 2002 Aug;110(2 Pt 1):285-91 [PMID: 12165580]
  25. Infect Control Hosp Epidemiol. 2003 May;24(5):317-21 [PMID: 12785403]
  26. J Pediatr. 2007 Sep;151(3):260-5, 265.e1 [PMID: 17719934]
  27. Pediatrics. 2006 Sep;118(3):874-81 [PMID: 16950976]
  28. CMAJ. 1992 Feb 15;146(4):473-81 [PMID: 1306034]
  29. Pediatr Crit Care Med. 2003 Apr;4(2):220-6 [PMID: 12749656]
  30. Acta Paediatr. 2004 Jun;93(6):786-90 [PMID: 15244228]
  31. Expert Opin Pharmacother. 2005 Oct;6(13):2257-69 [PMID: 16218886]
  32. J Hosp Infect. 2005 Dec;61(4):300-11 [PMID: 16221510]
  33. Vaccine. 2006 Apr 12;24 Suppl 2:S2-65-9 [PMID: 16823932]
  34. Int J Artif Organs. 2005 Nov;28(11):1157-62 [PMID: 16353122]
  35. Arch Dis Child Fetal Neonatal Ed. 2004 Jul;89(4):F331-5 [PMID: 15210669]
  36. Med Care. 2000 Jun;38(6):583-637 [PMID: 10843310]
  37. Curr Opin Pharmacol. 2006 Oct;6(5):473-9 [PMID: 16870507]
  38. Pediatr Infect Dis J. 2007 Aug;26(8):678-83 [PMID: 17848877]
  39. Drugs. 2006;66(14):1797-806 [PMID: 17040111]
  40. N Engl J Med. 2002 Feb 14;346(7):491-6 [PMID: 11844850]
  41. Infect Control Hosp Epidemiol. 2005 Jul;26(7):616-21 [PMID: 16092741]
  42. Eur J Pediatr. 2007 Apr;166(4):319-25 [PMID: 17051356]
  43. Pediatrics. 2009 May;123(5):e790-6 [PMID: 19403471]
  44. J Perinatol. 2006 May;26(5):290-5 [PMID: 16598296]
  45. Clin Perinatol. 2008 Mar;35(1):223-49, x [PMID: 18280884]
  46. J Pediatr. 2001 Dec;139(6):821-7 [PMID: 11743507]
  47. Pediatrics. 2007 Nov;120(5):937-45 [PMID: 17974729]
  48. Infect Control Hosp Epidemiol. 2006 Feb;27(2):139-45 [PMID: 16465630]
  49. Neurology. 2008 Jul 1;71(1):21-7 [PMID: 18591502]
  50. J Chronic Dis. 1978;31(11):697-704 [PMID: 730825]
  51. Infect Control Hosp Epidemiol. 2005 Feb;26(2):157-60 [PMID: 15756886]
  52. Eur J Clin Microbiol Infect Dis. 2009 Jul;28(7):831-3 [PMID: 19184141]
  53. Antimicrob Agents Chemother. 2009 Jul;53(7):2879-86 [PMID: 19380597]
  54. Braz J Med Biol Res. 2004 Sep;37(9):1345-51 [PMID: 15334200]
  55. Pediatrics. 2004 Oct;114(4):953-61 [PMID: 15466090]
  56. Am J Med. 2006 Mar;119(3):275.e15-23 [PMID: 16490475]
  57. Am J Dis Child. 1989 Jan;143(1):34-9 [PMID: 2910044]

Grants

  1. U01 GM070708/NIGMS NIH HHS
  2. U54 GM088491/NIGMS NIH HHS
  3. U54 GM088491-01/NIGMS NIH HHS
  4. 1U54GM088491-0109/NIGMS NIH HHS

MeSH Term

Computer Simulation
Cost-Benefit Analysis
Humans
Infant, Newborn
Methicillin-Resistant Staphylococcus aureus
Models, Economic
Staphylococcal Infections
Staphylococcal Vaccines

Chemicals

Staphylococcal Vaccines
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Word Cloud

Created with Highcharts 10.0.0aureusSvaccineStaphylococcusinfectionspotentialeconomicneonatescontinuingmorbiditymortalityassociatedespeciallymethicillin-resistantMRSAmotivatedcallsmakedevelopmentresearchprioritydevelopeddecisionanalyticcomputersimulationmodeldetermineimpactresultssuggestneonatalpopulationstronglycost-effectivemanysituationsdominantwiderangeefficacies10%costsattackrates>or=1%value

Similar Articles

Cited By